Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation
Annals of Hematology · 2025
DOI: 10.1007/s00277-025-06416-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2025. Verfasst von Carol Yuk Man Cheung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Queen Mary Hospital, Hong Kong SAR, People's Republic of China. drcarolcheung@gmail.com. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Protein Kinase Inhibitors. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) usually requires long-term therapy with tyrosine kinase inhibitors (TKIs). While these agents have markedly advanced the clinical management and prognosis of CML, a subset of patients experience treatment resistance or suboptimal response, necessitating multiple lines of TKI therapy. Few treatment options exist for patients who are resistant or intolerant to first- and second-line therapies. To provide guidance for the management of patients in chronic-phase failing at least two lines of treatment, a literature review followed by consensus generation from an expert panel with a modified Delphi process was conducted. This was followed by a meeting in person and subsequent online iterations for the establishment of a list of consensus guidelines. Consensus was defined as ≥ 75% of respondents selecting either 'accept completely' or 'accept with some reservation'. Overall, 17 statements were formulated covering five topics - defining treatment failure and acceptable treatment response, in terms of efficacy and intolerance; sequencing therapy to prevent disease progression and improve quality of life; managing patients with broad resistance, specific mutations, and risk of cardiovascular events; considering timing of cytogenetic or molecular response; and mitigating risk when using novel therapies and allogeneic hematopoietic stem cell transplantation. These comprehensive, evidence-based recommendations will assist clinicians in managing their patients with CML in third and later lines of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Queen Mary Hospital, Hong Kong SAR, People's Republic of China. drcarolcheung@gmail.com.
- Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong SAR, People's Republic of China.
- Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, People's Republic of China.
- Department of Medicine, Tseung Kwan O Hospital, Hong Kong SAR, People's Republic of China.
- Department of Medicine, Queen Elizabeth Hospital, Hong Kong SAR, People's Republic of China.
- United Christian Hospital, Hong Kong SAR, People's Republic of China.
Zitieren
APA
Cheung, C. Y. M., Ha, C. Y., Kho, B., Lau, C. K., Lau, J. S. M., Lin, S. Y., Mak, V. W. M., Wong, R. S. M., & Kwong, Y. L. (2025). Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation. Annals of Hematology. https://doi.org/10.1007/s00277-025-06416-9
Vancouver
Cheung CYM, Ha CY, Kho B, Lau CK, Lau JSM, Lin SY, et al. Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation. Annals of Hematology. 2025. doi:10.1007/s00277-025-06416-9
BibTeX
@article{Cheung2025,
author = {Cheung, Carol Yuk Man and Ha, Chung Yin and Kho, Bonnie and Lau, Chi Kuen and Lau, June Sze Man and Lin, Shek Ying and Mak, Vivien Wai Man and Wong, Raymond Siu Ming and Kwong, Yok Lam},
title = {Management of chronic-phase CML in later lines: a Hong Kong consensus recommendation},
journal = {Annals of Hematology},
year = {2025},
doi = {10.1007/s00277-025-06416-9}
}
EUVIMED